Genetics of Chemotherapy-Related Amenorrhea in Breast Cancer Survivors


About this study

The purpose of this study is to assess genetic predictors of chemotherapy-related amenorrhea in breast cancer survivors of both European and non-European ancestry.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Women affiliated with the Army of Women program
  • First diagnosed with breast cancer within the last 10 years
  • First diagnosed with breast cancer before turning 50 years old
  • Received chemotherapy for breast cancer, with first dose given before turning 50 years old
  • Has never been diagnosed with a cancer other than breast cancer (besides non-melanoma skin cancer or carcinoma in situ of the cervix)
  • Willing to allow us to access all medical records pertaining to breast cancer diagnosis and treatment
  • Willing to provide a saliva sample for DNA analysis by our study team
  • Willing to complete a short survey regarding breast cancer treatments, menses, and pregnancies

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Kathryn Ruddy, M.D.

Closed for enrollment

Contact information:

Catherine Erding


More information


Publications are currently not available

Mayo Clinic Footer